Over the past 30 years, the share of biotechnologically derived drug products in the arsenal of medicinal products has been growing steadily. These drug products include proteins, such as monoclonal antibodies, antibody fragments, endogenous or modified hormones, and growth factors, as well as antisense oligonucleotides, RNA, DNA preparations for gene therapy, and stem cell therapies. In 2017, 12 out of the 46 approved marketing authorizations for new molecular entities by the US Food and Drug Administration (FDA) were biotech products, mainly from the monoclonal antibody family (Mullard 2018).